Navigation Links
Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Date:11/1/2011

HAYWARD, Calif., Nov. 1, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced that it will be presenting data on arhalofenate, a potential best-in-class treatment for gout, at the 2011 ACR/AHP Annual Scientific Meeting on Wednesday, November 9, 2011 in Chicago, IL.  The presentation will describe the results of a pooled analysis of four Phase 2 studies in patients with type 2 diabetes, a subset of which exhibited hyperuricemia. The analysis shows that the patients experienced statistically and clinically significant reductions in serum uric acid that were fully retained in patients with mild-to-moderate renal insufficiency.  

Presentation Title: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes"

Session Title: Metabolic and Crystal Arthropathies II: Concurrent Session on the Anti-Gout Medications – Dosing, Adverse Effects, and Economic Burden

Date/Time:  Wednesday, November 9, 2011 from 10:15 AM - 10:30 AM CST

Location: McCormick Place Convention Center: W 474 A

About Hyperuricemia and Gout

Gout is a chronic, progressive rheumatic disease, caused by an inflammatory response to uric acid crystals deposited in joints and soft tissues as a result of excess uric acid in the blood (hyperuricemia). Elevated sUA levels cause urate crystals for form in joints triggering acute arthritic flares, chronic destructive arthropathy and formation of tophi.  According to the NHANES (2007-2008) study, the incidence of hyperuricemia in the US is over 45 million and over 8 million have progressed to a gout diagnosis.  

About Metabolex

Metabolex is a privately
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
2. Metabolex Initiates Phase 1 Trial of MBX-2982
3. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... May 11 th before the open, followed by a ... results and business outlook. Participants should call (888) ... (International) and request the InspireMD call. A live webcast of ...
(Date:5/5/2015)... , May 5, 2015 GW Pharmaceuticals ... "Company"), a biopharmaceutical company focused on discovering, developing ... product platform, announced today the closing of the ... by GW of 1,600,000 American Depositary Shares (ADSs) ... gross proceeds of approximately $179.2 million (before deducting ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
Breaking Medicine Technology:InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 2GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 3GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately $179.2 Million on the NASDAQ Global Market 4Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3
... Associated Foot & Ankle Specialists,today announced it ... diabetes,to participate in the MATRIX clinical trial. The ... Excellarate, for the potential treatment of,patients with non-healing ... to stimulate the process of wound healing., ...
... to Healthcare Market, ORLANDO, Fla., Feb. ... (NYSE: HRS ), an international communications ... Cancer Treatment,Services International (CTSI) to advance the ... provide advanced imaging and information,systems that assure ...
Cached Medicine Technology:Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
(Date:5/6/2015)... 2015 The beverage industry has grocery ... Miracles organic tea and superfruit fusions stands out among ... sweetened with agave, these delicious juice blends are making ... healthier ways to hydrate. , In collaboration with National ... to raise a bottle of Lemongrass Tea and Ginseng, ...
(Date:5/5/2015)... With ProPoint: Hand Drawn, users can point, underline, ... X . With ProPoint: Hand Drawn, users can also ... customize each preset all with a click of a mouse. ... fully customizable effect presets all within Final Cut Pro X. ... underlines, and more. , ProPoint: Hand Drawn on-screen controls ...
(Date:5/5/2015)... May 05, 2015 Private equity consultant ... LLC has announced that its dental stem cell biobank ... increased once again--in April, 2015 –and posted yet another ... increased record volume and represents a significant 54% increase ... stem cell biobank is conducted via the Store-A-Tooth brand. ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Carlini CPA, ... Trail, Monroe, Matthews, Charlotte and surrounding areas. The company ... of accounting. This company provides assistance in making informed ... they prepare individual or corporate tax returns for their ... the cloud that allows clients (and Carlini CPA) to ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), a ... peripheral nerve repair market, reported record revenue of $4.95 ... compared to $3.14 million in the year-ago first quarter. ... portfolio of nerve repair products - Avance® Nerve ... and our solid sales execution delivered another record quarter ...
Breaking Medicine News(10 mins):Health News:Say Cheers to National Beverage Day with Little Miracles 2Health News:FCPX Plugin Developer Pixel Film Studios release Propoint Hand Drawn 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... Q2 2007 Levels, - STAAR Announces Internet Marketing Campaign with ... ... MONROVIA, Calif., June 12 STAAR Surgical,Company (Nasdaq: STAA ), a ... Visian ICL(TM),(Implantable Collamer Lens) sales in the U.S. for the second quarter ...
... for Model Evaluation; Dr. Mike Dunlavey Will Present Simplified ... ... June 12 Pharsight,Corporation (Nasdaq: PHST ), a leading ... drug,development, today announced that Pharsight software development experts,will deliver two ...
... time is associated with overweight in children and adolescents, ... reduced REM sleep, according to a research abstract that ... 22nd Annual Meeting of the Associated Professional Sleep Societies ... PhD, of the University of Pittsburgh, focused on 335 ...
... has announced that it has,been awarded the prestigious Emerging ... Wound Management category., KFH,s CEO, Henk Snyman, MD, ... respected company such as Frost & Sullivan. We have,achieved ... to create,a continuous stream of state-of-the-art, portable medical devices ...
... Mich. A type of stroke that can strike at ... be more common in women and Mexican-Americans than in non-Hispanic ... of Michigan Stroke Program. , In a paper published online ... report that women had a 74 percent greater chance of ...
... GROVE, Ill., June 11 Lifeway Foods,Inc., (Nasdaq: ... kefir, announced today that they are now using milk ... certified hormone free milk comes,with a Farmers Pledge, which ... change came as a response to a growing demand ...
Cached Medicine News:Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 3Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 4Health News:Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting 2Health News:Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting 3Health News:REM sleep associated with overweight in children and adolescents 2Health News:REM sleep associated with overweight in children and adolescents 3Health News:Kingfisher Healthcare (KFH) Wins Prestigious Frost & Sullivan Best Practices Award 2Health News:Women, Mexican-Americans at higher risk of ruptured brain aneurysm 2Health News:Women, Mexican-Americans at higher risk of ruptured brain aneurysm 3Health News:Lifeway Foods Switches to 100% Certified Hormone Free Milk 2
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
CranioFix2 is the next generation CranioFix Titanium Clamp System, which is up to 40% faster than the original CranioFix and all flap fixation systems on the market....
... P-2000 FastPach is an accurate, reliable, ... glaucoma screenings. It works off of ... charging of the device a breeze. ... controls make operating and viewing results ...
... PalmScan A2000] device is intended as a ... ultrasound,technology, and thus may be used to ... depth (ACD), and lens thickness (LT) of ... intended for calculating the optical power of ...
Medicine Products: